Perspectives of choroidal neovascularization therapy.
Vision loss secondary to Choroidal Neovascularization (CNV) is becoming a major disease condition in developed world. CNV is typically secondary to Age-related Macular Degeneration (AMD) and these conditions are major, and also substantially increasing, causes of blindness among aged people. Several therapeutic options are currently available to treat CNV with variable efficacy on disease progress. Among existing treatments there are laser photocoagulation, photodynamic therapies, local corticosteroids and, more recently, the use of anti-angiogenic factors. Although by these treatments very effective results are obtained and their further improvement is still possible, it is also reasonable and necessary to look for more successful and definitive alternatives. The research in this direction is already very active and it can be expected that applications of the more recent molecular technologies will bring important advances also for CNV. These will likely regard the use of gene therapy and of new target specific factors. Gene therapies methodologies are rapidly becoming closer to current clinical use and, since the eye is a particularly favourable organ for drug delivery, their ocular use is probably going to be among the first successful applications of these techniques. In addition to its specific technology, gene therapy requires the knowledge of specific genes to be modulated to adequately affect pathogenesis and progression of the disease in which has to be applied. This will also be true for the use of novel target specific drugs such as antibodies and other molecules able to affect cellular factors and pathways also related to disease development. For this reason, a major direction of future CNV therapies will be the identification of specific gene, gene products, metabolic pathways and metabolites related to the disease. This information, in addition to be suitable for gene and target specific therapies, will also allow the development of new procedures to improve diagnosis and/or prognostic evaluation of the disease.
Caputo
M
M
Dipartimento di Scienze Farmaceutiche, Università di Salerno, Fisciano, Italy.
Zirpoli
H
H
Di Benedetto
R
R
De Nadai
K
K
Tecce
M F
MF
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D001766:Blindness / Q000209:etiology / Q000517:prevention & control*; D020256:Choroidal Neovascularization / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000639:trends; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation; D008268:Macular Degeneration / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D050997:Nanomedicine / Q000639:trends; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D016372:RNA, Antisense / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids; D017319:Photosensitizing Agents; D016372:RNA, Antisense